IN THIS ISSUE:

Notice
New Forms for Research Grant, RCDA, and
Individual National Research Service
Award (Fellowship) Applications.................... Page 1
Index - APPLICATIONS

Announcement
Biomedical Research Support Grant
Applications for Fiscal Year 1983 .................. Page 3
Division of Research Resources
Index - RESEARCH RESOURCES, DIVISION OF

Announcement
Small Grants Program for Pilot Projects
Biotechnology Resources Program ................. Page 5
Division of Research Resources
Index - RESEARCH RESOURCES, DIVISION OF

Announcement
Genetic Sequence Data Bank....................... Page 8
National Institute of General
Medical Sciences
Index - NIGMS

Announcement
Research Grants on Small Animal Models
for Screening Antiepileptic Drugs ............... Page 9
National Institute of Neurological and
Communicative Disorders and Stroke
Index - NINCDS

(Continued)

HAVE YOU MOVED?

If your present address differs from that shown on
the address label, please send your new address to:
Grants and Contract Guide Distribution Center,
National Institutes of Health, Room B338810, Building 31,
Bethesda, Maryland 20892, and attach your address label
to your letter. Prompt notice of your change of address
will prevent your name from being removed from our
mailing list.

The GUIDE is published at irregular intervals to announce scientific initiatives and to provide
policy and administrative information to individuals and organizations who need to be kept informed
of opportunities, requirements, and changes in grants and contracts activities administered by the
National Institutes of Health.

Two types of supplements are published by the respective awarding units. Those printed on yellow
paper concern contracts: solicitations of sources and announcement of availability of requests for
proposals. Those printed on blue paper concern invitations for grant applications in well-defined
scientific areas to accomplish specific program purposes.
Announcement
Use of Growth Factors, Maturation Factors and Anti-Growth Factors in Animal Tumor Models .................................................. Page 12
Biological Response Modifiers Research
National Cancer Institute
Index - NCI

Announcement
Development of Genetically Engineered Cell Products ........................................ Page 14
Biological Response Modifiers Research
National Cancer Institute
Index - NCI

Announcement
Use of Tumor Associated Antigens as Immunogens ........................................... Page 16
Biological Response Modifiers Research
National Cancer Institute
Index - NCI

Announcement
Development of Cell Lines Producing Lymphokines and Cytokines .................. Page 18
Biological Response Modifiers Research
National Cancer Institute - NCI
NEW FORMS FOR RESEARCH GRANT, RCDA, AND INDIVIDUAL NATIONAL RESEARCH SERVICE AWARD (FELLOWSHIP) APPLICATIONS

Grant Application Forms PHS 398 and PHS 2590

The new application forms for Public Health Service grant (PHS 398, revised May 1982) and for continuation of such a grant (PHS 2590, revised May 1982) are now available for use by the scientific community. Copies of these forms may be obtained by writing to:

Chief, Office Services Branch
Division of Research Grants
National Institutes of Health
Bethesda, Maryland 20205

Individual copies may also be obtained by writing to:

Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Bethesda, Maryland 20205

While the new forms contain a number of changes, the most significant ones are in the areas of research involving human subjects or vertebrate animals. Therefore, if proposed projects involve human subjects or vertebrate animals, use the new forms for submissions after January 1983. In those cases where human subjects or animals are not involved, please continue to use the 1980 versions of the PHS 398 and PHS 2590 forms until supplies are exhausted.

Individual NRSA Forms PHS 416-1 and PHS 416-9

The new application forms for an Individual National Research Service Award (PHS 416-1, revised December 1981) and for continuation of such an award (PHS 416-9, revised December 1981) will soon be available. The new forms for competing applications should be used for the February 1, 1983 receipt date. Copies of these forms may be obtained by writing to:

Chief, Office Services Branch
Division of Research Grants
National Institutes of Health
Bethesda, Maryland 20205

Individual copies may also be obtained by writing to the following address:

Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Bethesda, Maryland 20205
NIH Research Career Development Awards (RCDAs)

NIH Research Career Development Awardees (K04) will start using the PHS 2590 continuation application form in the near future. Coincident with this change, the institution control offices will be asked to distribute the application forms. By approximately December 1, 1982, mailings to control offices will include a computerized face page and a set of supplemental instructions for RCDA (K04) continuation applications. The May 1982 revision of the PHS 2590 form will have to be used. Questions on this conversion should be directed to:

Mr. Nicholas Moriarty  
Division of Research Grants  
National Institutes of Health  
Bethesda, Maryland 20205  

Telephone: (301) 496-7221

Applicants for new (competing) RCDAs should continue to use the current additional instructions booklet.
ANNOUNCEMENT

BIOMEDICAL RESEARCH SUPPORT GRANT APPLICATIONS

FOR FISCAL YEAR 1983

DIVISION OF RESEARCH RESOURCES

Application Receipt Date: January 1, 1983

I. BACKGROUND

The Biomedical Research Support Grant (BRSG) Program is specifically designed to provide funds on a continuing basis to eligible institutions heavily engaged in health-related research to strengthen their programs by allowing flexibility available to the institutions to meet emerging opportunities in research; to explore new and unorthodox ideas; and to use these research funds in ways and purposes which they (the institutions), in their judgment, feel would contribute effectively to the furtherance of their research program.

II. ELIGIBILITY

Awards are made to non-profit institutions, not directly to individual investigators. Health professional schools, other academic institutions, hospitals, state and municipal health agencies, and research organizations may apply if the institution received a minimum of three allowable PHS biomedical or health-related behavioral research grants, totaling $500,000 (including direct and indirect costs), awarded during FY 1982 (October 1, 1981 through September 30, 1982). Federal institutions and institutions located in a foreign country are not eligible.

NOTE: Other academic includes, as a single eligible component, all other schools, departments, colleges and free-standing institutes of the institution except the health professional schools.

III. AWARD CONDITIONS

The BRSG award is for one year and must be renewed annually. The start date is April 1. It is estimated that approximately 420 BRSG awards will be made in FY 1983.

The BRSG program is described in the catalog of Federal Domestic Assistance, No. 13.337, Biomedical Research Support. Grants will be awarded under the authority of the Public Health Service Act, Section 301 (a) (3); Public Law 86-798, (42 USC 241) and administered under PHS grant policies and Federal Regulations 45 CFR Part 74 and the Biomedical Research Support Grant Information Statement and Administrative Guidelines. This program is not subject to A-95 Clearinghouse of Health Systems Agency review.
The amount of each BRSG award is based upon a formula that is applied to the total of direct and indirect costs awarded for allowable PHS research grants.

IV. METHOD OF APPLYING

BRSG application kits (Form NIH-147-1) will be mailed on or about November 26 to institutions that, according to NIH records, are eligible to apply for a BRSG.

Completed BRSG applications must be received by January 1, 1983.

If an institution believes that it is eligible and has not received an application kit by December 6, call Mrs. Gilda Polletto, Grants Management Specialist, Area Code: (301) 496-5131.
ANNOUNCEMENT

SMALL GRANTS PROGRAM FOR PILOT PROJECTS

BIOTECHNOLOGY RESOURCES PROGRAM

DIVISION OF RESEARCH RESOURCES

Application Receipt Dates: February 1, June 1, October 1

The Biotechnology Resources Program (BRP) of the Division of Research Resources (DRR) has initiated a small grant award beginning with the February 1 application receipt date in 1983. The BRP expects to make approximately ten to twenty awards for Fiscal Year 1983, contingent on receipt of meritorious applications and appropriated funds.

I. PURPOSE OF THE AWARD

This is a one-year, non-renewable award for pilot projects in high technology and engineering related to biomedical research. The projects should involve feasibility studies of innovative and high-risk ideas and provide a basis for more extended research in the project's technology.

The purpose of the Biotechnology Resources small grants program is to:

1. Enable examination of a new technology for its usefulness in biomedical research; or
2. Develop significant changes in existing technology important to biomedical research; or
3. Translate scientific notions into a basis for a future technology.

II. ELIGIBLE APPLICANTS

This program is open to both non-profit and for-profit organizations and is designed to support:

1. Engineers and other scientists with experience primarily in fields other than biomedical research. (The BRP has a New Investigator Research Award program for recently trained or less experienced scientists.)

This program is described in the Catalog of Federal Domestic Assistance No. 13.371, Biotechnology Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 42 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.
2. Investigators whose research career in high technology has been interrupted and is to be resumed.

3. Investigators changing field of research.

4. Investigators at minority institutions or located in a largely non-research environment such as a small business.

5. Established investigators needing quick support for a high technology proposal for which no other funds are available.

The award may not be used to supplement support for an ongoing project.

III. APPLICATION AND REVIEW PROCEDURE

Applications shall be submitted on Form PHS 398, available at most institutional business offices or from the Division of Research Grants, NIH. Because the format for preparing this application is different from that used for regular research grants, additional information and instructions should be obtained from BRP staff contact listed below. Applications must adhere to this format to be responsive. Unresponsive applications will be returned to the applicant without review. An accelerated review will be scheduled as follows:

<table>
<thead>
<tr>
<th>Receipt Date</th>
<th>Institute Committee Review</th>
<th>Council Review</th>
<th>Earliest Date for Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annually</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>February 1</td>
<td>March - April</td>
<td>May - June</td>
<td>June</td>
</tr>
<tr>
<td>June 1</td>
<td>July - September</td>
<td>Sept - Oct</td>
<td>November</td>
</tr>
<tr>
<td>October 1</td>
<td>November - January</td>
<td>Jan - Feb</td>
<td>February</td>
</tr>
</tbody>
</table>

Applications recommended for approval will either be funded or withdrawn immediately after review by the National Advisory Research Resources Council.

IV. REVIEW CRITERIA

Applications will be evaluated with respect to the following criteria: The significance and scientific merit of the proposed project; its characterization as an innovative and high-risk pilot project in high technology or engineering which is relevant to biomedical research and will provide a basis for more extended research; the methodology, including choice of experimental methods, equipment or materials; the investigator's background and training for carrying out the project; adequacy of the available and requested facilities; and the adequacy of justifications presented for budget requests.

V. FUNDING CRITERIA

Applications will compete with each other in accordance with scientific merit and the purposes of the small grant program.

VI. TERMS OF THE AWARD

The award will provide a maximum of $15,000 (direct costs) for personnel consultants, supplies, small equipment, and travel required by the project.
VII. STAFF CONTACT

For further information prospective applicant are strongly urged to contact:

Dr. William R. Baker, Jr.
Special Assistant for Biomedical Engineering
Biotechnology Resources Program
Division of Research Resources
National Institutes of Health
Building 31 - Room 5B43
9000 Rockville Pike
Bethesda, Maryland 20205

Telephone: (301) 496-5411
ANNOUNCEMENT

GENETIC SEQUENCE DATA BANK

NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

The National Institute of General Medical Sciences (NIGMS) announces the international availability of a new public resource, the Genetic Sequence Data Bank (GenBank). GenBank is a repository of all published nucleic acid sequences greater than fifty nucleotides in length, annotated and checked for accuracy. This resource, co-sponsored by the NIGMS, National Cancer Institute, National Institute of Allergy & Infectious Diseases, Division of Research Resources, Department of Energy, Department of Defense and the National Science Foundation, is of particular interest to geneticists and molecular biologists. Nucleic acid sequences are available from the bank for a modest fee on computer readable magnetic tape and by limited dial-up on-line access. In addition, a yearly hard-copy edition of the data bank will be available.

For information write:

GenBank
c/o Computer Systems Division
Bolde Beranek & Newman, Inc.
10 Moulton Street
Cambridge, Massachusetts 02238
ANNOUNCEMENT

RESEARCH GRANTS ON SMALL ANIMAL MODELS
FOR SCREENING ANTIEPILEPTIC DRUGS
NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE
DISORDERS AND STROKE

Application Receipt Dates: March 1, July 1, November 1

I. INTRODUCTION

The Epilepsy Branch, Neurological Disorders Program of the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS), encourages the submission of research grant applications (RO1) for the development of small animal models to be used in the screening of antiepileptic drugs.

II. BACKGROUND

Even though more than 2 million Americans currently suffer from epilepsy, the development of effective yet nontoxic antiepileptic drugs has proceeded slowly. In 1977, the Commission for the Control of Epilepsy and its Consequences recommended continued Federal funding for new drug development and advised the expansion of animal screening for potential antiepileptic drugs. To keep pace with the development of new concepts in epileptogenesis, there needs to be a concerted long-range effort by the scientific community to provide new, easily used models of modest cost for screening potential anticonvulsants. Current seizure models evaluate drug effects on the spread of seizures induced by maximum electroshock (MES) and on seizure threshold when the threshold is lowered by subcutaneous pentylenetetrazol. These tests have not changed substantially since their development nearly 50 years ago. Despite the fact that they are inexpensive, easy to do, and can be standardized, there is increasing uncertainty about the relationships between the models and modern concepts of epileptogenesis. The current models therefore may potentially impede progress by not detecting a promising useful drug. False negatives may cause a whole class of compounds to be set aside and never identified as having therapeutic potential. The Epilepsy

This program is described in the Catalog of Federal Domestic Assistance No. 13.854, Fundamental Neurosciences. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.
Branch, neurological Disorders Program, NINCDS, encourages the submission of applications for the support of basic research on development of new animal models specifically for the screening of antiepileptic drugs.

III. RESEARCH GOALS

It is recognized that good animal models expedite research by permitting drugs to be tested with the confidence that results can be extrapolated accurately to humans. The ideal model for testing the effects of antiepileptic drugs would be one that closely approximates human epilepsy, is simple and inexpensive, and from which results could be obtained easily and quickly. Several existing methods of inducing seizures may be potentially useful for the development of models of epilepsy for evaluation of anticonvulsant drugs. Research grant applications should focus on validation of the relationship of seizure models to human epilepsy and demonstration that the animal models are accurate, reproducible, and sensitive to a variety of drugs and compounds. The primary research goal therefore is the development of models which 1) lend themselves to rapid and inexpensive screening of new antiepileptic drugs; 2) have a validity for seizures in man; 3) are superior to the standard assays already in use; and 4) are capable of predicting anticonvulsant activity for one or more of the specific types of seizures in man. To validate the model, it must be demonstrated that 1) electrographic studies show the presence of epileptic-like activity in the EEG, and 2) clinical seizure activity is observable.

IV. MECHANISMS OF SUPPORT

Support for this program will be through the regular research project grant-in-aid. Each successful applicant will plan, direct, and carry out the individual research project.

V. APPLICATION AND REVIEW PROCEDURES

Applications should be prepared on form PHS 398 (Revised 5/80) following instructions contained in the application kit. Application kits are available from most institutional business offices, or may be obtained from the Division of Research Grants, at the address given below.

Applications must be responsive to the program announcement and the goals of NINCDS. They will be judged on scientific merit and program relevance in accordance with NIH policy and procedures involving peer review. An initial review will be made by an appropriate study section of the Division of Research Grants. A second level of review will be made by the National Advisory Neurological and Communicative Disorders and Stroke Council.

Deadline dates for the receipt of applications are March 1, July 1, and November 1 annually.

The phrase "NINCDS Program Announcement for Small Animal Models for Screening Antiepileptic Drugs" should be typed in space No. 2 of the face page of the application. The original and six copies of the application should be mailed to:

Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
5333 Westbard Avenue
Bethesda, Maryland 20205
One copy of the application is to be sent to the addressee below. Also, for further information applicants may contact:

William H. Pitlick, M.D.
Health Scientist Administrator
Epilepsy Branch
Neurological Disorders Program
National Institute of Neurological and Communicative Disorders and Stroke
Federal Building - Room 118
7550 Wisconsin Avenue
Bethesda, Maryland 20205

Telephone: (301) 496-1917
ANNOUNCEMENT

USE OF GROWTH FACTORS, MATURATION FACTORS AND ANTI-GROWTH FACTORS IN ANIMAL TUMOR MODELS

BIOLOGICAL RESPONSE MODIFIERS RESEARCH

NATIONAL CANCER INSTITUTE

Application Receipt Dates: March 1, July 1, November 1

The National Cancer Institute's (NCI) Division of Cancer Treatment (DCT) desires to expand its support of clinical treatment research. The program is seeking applications for research grants concerned with the therapeutic effects of growth factors, maturation factors, and monoclonal antibody to growth factors on the growth and metastasis of cancer in animal tumor models. In making this program announcement it is not the intent of the NCI to make or imply any delimitation related to biological response modifiers research, but rather to stimulate investigator initiated research in biological response modifiers.

Applications in response to this announcement will be reviewed in accordance with the usual National Institutes of Health (NIH) peer review procedures. They will first be reviewed for scientific and technical merit by a review group composed mostly of non-Federal scientific consultants. Following this initial review, the application will be evaluated for program relevance by the National Cancer Advisory Board. The review criteria customarily employed by the NIH for regular research grant applications will prevail.

DEADLINE

Applications will be accepted in accordance with the usual NIH receipt dates for new applications. Deadline dates are: March 1, July 1, November 1.

METHOD OF APPLYING

Applications should be submitted on form PHS 398, which is available in the grants and contracts business office at most academic and research institutions or from the Division of Research Grants (DRG), NIH. In space #2 on the first page of this form, indicate the title of the Program Announcement.

This program is described in the catalog of Federal Domestic Assistance No. 13.395, Cancer Treatment Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.
Additionally, a brief covering letter should accompany the application indicating it is being submitted in response to this program announcement. The original and six copies of the application should be sent or delivered to:

Application Receipt Office  
Division of Research Grants  
National Institutes of Health  
Westwood Building - Room 240  
Bethesda, Maryland 20205  

For further information, investigators are encouraged to contact:

Dr. Cedric W. Long  
Program Director for Pre-Clinical Trials, BRB, BRMP  
Building 426 - Room 1  
Frederick Cancer Research Facility  
Frederick, Maryland 21701  

Telephone: (301) 695-1098  

In order to alert the DCT to the submission of proposals with primary thrust directed to biological response modifiers research, a copy of the covering letter should be sent under separate cover to Dr. Long.
ANNOUNCEMENT

DEVELOPMENT OF GENETICALLY ENGINEERED CELL PRODUCTS

BIOLOGICAL RESPONSE MODIFIERS RESEARCH

NATIONAL CANCER INSTITUTE

Application Receipt Dates: March 1, July 1, November 1

The National Cancer Institute's (NCI) Division of Cancer Treatment (DCT) desires to expand its support of clinical treatment research. The program is seeking applications for research grants concerned with the development of genetically engineered cell products for therapeutic application as biological response modifiers. This announcement will support diverse approaches into the use of genetic engineering to transpose genes coding for biological response modifiers such as interferons, lymphokines, growth factors and other gene products into microbial organisms for a large scale production, isolation, purification and characterization of these factors for therapeutic application as biological response modifiers. In making this program announcement it is not the intent of the NCI to make or imply any delimitation related to biological response modifiers research, but rather to stimulate investigator initiated research in biological response modifiers.

Applications in response to this announcement will be reviewed in accordance with the usual National Institutes of Health (NIH) peer review procedures. They will first be reviewed for scientific and technical merit by a review group composed mostly of non-Federal scientific consultants. Following this initial review, the application will be evaluated for program relevance by the National Cancer Advisory Board. The review criteria customarily employed by the NIH for regular research grant applications will prevail.

DEADLINE

Applications will be accepted in accordance with the usual NIH receipt dates for new applications. Deadline dates are: March 1, July 1, November 1.

METHOD OF APPLYING

Applications should be submitted on form PHS 398, which is available in the grants and contracts business office at most academic and research institutions or from the Division of Research Grants (DRG) NIH. In space #2 on the first page of this form, indicate the title of the program announcement.

This program is described in the catalog of Federal Domestic Assistance No. 13.395, Cancer Treatment Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.
Additionally, a brief covering letter should accompany the application indicating it is being submitted in response to this program announcement. The original and six copies of the application should be sent or delivered to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
Bethesda, Maryland 20205

For further information, investigators are encouraged to contact:

Dr. Cedric W. Long
Program Director for Pre-Clinical Trials, BRB, BRMP
Building 426 - Room 1
Frederick Cancer Research Facility
Frederick, Maryland 21701

Telephone (301) 695-1098

In order to alert the DCT to the submission of proposals with primary thrust directed to biological response modifiers research, a copy of the covering letter should be sent under separate cover to Dr. Long.
ANNOUNCEMENT

USE OF TUMOR ASSOCIATED ANTIGENS AS IMMUNOGENS

BIOLOGICAL RESPONSE MODIFIERS RESEARCH

NATIONAL CANCER INSTITUTE

Application Receipt Dates: March 1, July 1, November 1

The National Cancer Institute's (NCI), Division of Cancer Treatment (DCT), desires to expand its support of clinical treatment research. The program is seeking applications for research grants concerned with the development of methods of immunization that evoke effective in vivo anti-tumor immunity using purified tumor associated antigens as immunogens. Isolation of tumor associated antigens is now possible using monoclonal antibodies. There is considerable uncertainty, however, how best to administer purified antigens in vivo to evoke effective anti-tumor immunity. Certain antigens may facilitate and others may inhibit tumor growth and metastases. The proposed studies should investigate this issue in both normal and tumor bearing animals using purified antigens as therapeutic agents. Preference will be given to non-viral tumor associated antigens on recently derived spontaneous or chemically induced fully syngeneic tumors although consideration will be given to viral coded tumor antigens and even normal cell surface alloantigens as model antigens. The use of various immunization schedules and adjuvants in therapy models with detailed monitoring of the host cellular and immune responses will be required. These studies must be directed toward optimizing the therapeutic effects of these antigens in vivo as demonstrated by protection studies against subsequent tumor growth. Proposals to investigate monoclonal antibody purified tumor associated antigens as therapeutic reagents in man may also be submitted. As in the animal models, homogenous preparations of high purity are preferred for these investigations. End points may be assessed by in vitro assays or by in vivo therapeutic effects. In making this program announcement it is not the intent of the National Cancer Institute to make or imply any delimitation related to biological response modifiers research, but rather to stimulate investigator initiated research in biological response modifiers.

Applications in response to this announcement will be reviewed in accordance with the usual National Institutes of Health (NIH) peer review procedures. They will first be reviewed for scientific and technical merit by a review group composed mostly of non-Federal scientific consultants. Following this initial review, the application will be

This program is described in the catalog of Federal Domestic Assistance No. 13.395, Cancer Treatment Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.
evaluated for program relevance by the National Cancer Advisory Board. The review criteria customarily employed by the NIH for regular research grant applications will prevail.

DEADLINE

Applications will be accepted in accordance with the usual NIH receipt dates for new applications. Deadline dates are March 1, July 1, November 1.

METHOD OF APPLYING

Applications should be submitted on form PHS 398, which is available in the grants and contracts business office at most academic and research institutions or from the Division of Research Grants (DRG), NIH. In space #2 on the first page of this form, indicate the title of the program announcement.

Additionally, a brief covering letter should accompany the application indicating it is being submitted in response to this program announcement. The original and six copies of the application should be sent or delivered to:

Application Receipt Office  
Division of Research Grants  
National Institutes of Health  
Westwood Building - Room 240  
Bethesda, Maryland 20205

For further information, investigators are encouraged to contact:

Dr. Cedric W. Long  
Program Director for Pre-Clinical Trials, BRB, BRMP  
Building 426 - Room 1  
Frederick Cancer Research Facility  
Frederick, Maryland 21701

Telephone: (301) 695-1098

In order to alert the DCT to the submission of proposals with primary thrust directed to biological response modifiers research, a copy of the covering letter should be sent under separate cover to Dr. Long.
ANNOUNCEMENT

DEVELOPMENT OF CELL LINES PRODUCING LYMPHOKINES AND CYTOKINES

BIOLOGICAL RESPONSE MODIFIERS RESEARCH

NATIONAL CANCER INSTITUTE

Application Receipt Dates: March 1, July 1, November 1

The National Cancer Institute's (NCI), Division of Cancer Treatment (DCT), desires to expand its support of clinical treatment research. The program is seeking applications for research grants concerned with the development of cell lines producing lymphokines and cytokines with therapeutic effects as biological response modifiers. This announcement will encourage research in the development of such cell lines and the development of methods to isolate, purify and characterize the therapeutic potential of the various products of these cell lines in appropriate test systems. These products may have a potential longterm usefulness in the treatment of cancer and/or in the alteration of biological responses in the course of cancer. In making this program announcement it is not the intent of the NCI to make or imply any delimitation related to biological response modifiers research, but rather to stimulate investigator initiated research in biological response modifiers.

Applications in response to this announcement will be reviewed in accord with the usual NIH peer review procedures. They will first be reviewed for scientific and technical merit by a review group composed mostly of non-Federal scientific consultants. Following this initial review, the application will be evaluated for program relevance by the National Cancer Advisory Board. The review criteria customarily employed by the NIH for regular research grant applications will prevail.

DEADLINE

Applications will be accepted in accordance with the usual NIH receipt dates for new applications. Deadline dates are March 1, July 1, November 1.

This program is described in the catalog of Federal Domestic Assistance No. 13.395, Cancer Treatment Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.
METHOD OF APPLYING

Applications should be submitted on form PHS 398, which is available in the grants and contracts business office at most academic and research institutions or from the Division of Research Grants (DRG), NIH.

In space #2 on the first page of this form, indicate the title of the program announcement. Additionally, a brief covering letter should accompany the application indicating it is being submitted in response to this program announcement. The original and six copies of the application should be sent or delivered to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
Bethesda, Maryland 20205

For further information, investigators are encouraged to contact:

Dr. Cedric W. Long
Program Director for Pre-Clinical Trials, BRB, BRMP
Building 426 - Room 1
Frederick Cancer Research Facility
Frederick, Maryland 21701

Telephone: (301) 695-1098

In order to alert the DCT to the submission of proposals with primary thrust directed to biological response modifiers research, a copy of the covering letter should be sent under separate cover to Dr. Long.